Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07312409 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2026 to Jun 30, 2027v3 Show 9 more changesShow less
    • Phase changed: not applicable → not specified
    • Recruitment opened
    • Study completion pushed from Mar 31, 2027 to Dec 31, 2027
    • Trial arms changed: 1 → 2
    • Start date changed from estimate of Apr 1, 2026 to Jun 1, 2026
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 11 words
    • Site details revised
    • Collaborators: 2 to 1
  2. Study description shortened, about 156 words
    • Collaborators: 1 to 2
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Millions have developed Long COVID (LC), and recent findings show an association between taurine deficiency (an amino acid) and symptoms in LC. Cost-effective and accessible interventions are needed to improve welfare and reduce healthcare costs. We will investigate the efficacy of 12-weeks of taurine supplementation (self-administered), on vascular function and the cardio/cerebrovascular responses to upright posture. We will measure resting vascular function with an EndoPAT device, resting heart rate variability, and the blood pressure, heart rate, and brain blood flow responses to 5 minutes of head-up tilt before and after weeks of taurine supplementation in LC. We hypothesize that the 12 weeks of supplementation will improve both resting vascular function and the responses to upright tilt. In turn, we hypothesize that symptoms will also improve (as measured by questionnaires).
Trial Details
NCT Number NCT07312409
Lead Sponsor York University
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions
(from sponsor)		 Long COVID Syndrome
Related terms Post-Acute COVID-19 Syndrome
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov